Literature DB >> 19754816

Histiocytic sarcomas in flat-coated retrievers: a summary of 37 cases (November 1998-March 2005).

J Fidel1, I Schiller, B Hauser, Y Jausi, C Rohrer-Bley, M Roos, B Kaser-Hotz.   

Abstract

Thirty-seven cases of histiocytic-like sarcomas (HLSs) in flat-coated retriever dogs were evaluated retrospectively. This tumour accounted for 36% of the malignant tumours seen in this breed during the study period. The median age at presentation was 8.2 years. Thirty-four dogs presented with a swelling or mass in a muscle group or surrounding a joint. The remaining three presented for rib (1), cutaneous (1) or primary splenic origin (1). A high rate of metastasis to local lymph nodes (45%), thorax (20%) and abdominal organs (20% confirmed) was seen. Overall metastastic rate by the time of death was 70%. The median survival for all dogs was 123 days. The most significant prognostic indicator was presence of distant metastasis at the time of diagnosis with median survival of 68 or 200 days, with or without metastasis, respectively. Chemotherapy and radiation therapy significantly improved survival. Dogs given chemotherapy survived a median of 185 versus 34 days for dogs that were not (P = 0.0008). Dogs treated with radiation survived a median of 182 versus 60 days for those that were not (P = 0.0282). Dogs receiving only palliative therapy survived a median of 17 versus 167 days in dogs receiving any kind of radiation, chemotherapy, surgery or combinations. A set protocol of radiation and CCNU (RTCCNU) induced minimal toxicity and provided a median survival of 208 versus 68 days for all other dogs. While this tumour carries a poor long-term prognosis in flat-coated retrievers, it is reasonable to treat these dogs for palliation of signs and extension of life.

Entities:  

Year:  2006        PMID: 19754816     DOI: 10.1111/j.1476-5810.2006.00090.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  24 in total

1.  Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997-2012).

Authors:  Raelene M Wouda; Mairin E Miller; Esther Chon; Timothy J Stein
Journal:  J Am Vet Med Assoc       Date:  2015-06-01       Impact factor: 1.936

2.  Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib.

Authors:  Marilia Takada; Lauren A Smyth; Jeremy Ml Hix; Sarah M Corner; Matti Kiupel; Vilma Yuzbasiyan-Gurkan
Journal:  Comp Med       Date:  2019-02-04       Impact factor: 0.982

3.  Suspected disseminated histiocytic sarcoma in a 3-year-old Perro de Presa Canario dog.

Authors:  Emily Denstedt
Journal:  Can Vet J       Date:  2014-02       Impact factor: 1.008

4.  Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers.

Authors:  Suzanne A Erich; Fernando Constantino-Casas; Jane M Dobson; Erik Teske
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

5.  Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells.

Authors:  S D Hafeman; D Varland; S W Dow
Journal:  Vet Comp Oncol       Date:  2011-05-18       Impact factor: 2.613

6.  Histiocytic sarcoma in 14 miniature schnauzers - a new breed predisposition?

Authors:  J A Lenz; E Furrow; L E Craig; C M Cannon
Journal:  J Small Anim Pract       Date:  2017-05-25       Impact factor: 1.522

Review 7.  Canine histiocytic neoplasia: an overview.

Authors:  Amanda K Fulmer; Glenna E Mauldin
Journal:  Can Vet J       Date:  2007-10       Impact factor: 1.008

8.  Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed.

Authors:  Jérôme Abadie; Benoit Hédan; Edouard Cadieu; Clotilde De Brito; Patrick Devauchelle; Catherine Bourgain; Heidi G Parker; Amaury Vaysse; Patricia Margaritte-Jeannin; Francis Galibert; Elaine A Ostrander; Catherine André
Journal:  J Hered       Date:  2009-06-16       Impact factor: 2.645

9.  Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior.

Authors:  Benoit Hedan; Rachael Thomas; Alison Motsinger-Reif; Jerome Abadie; Catherine Andre; John Cullen; Matthew Breen
Journal:  BMC Cancer       Date:  2011-05-26       Impact factor: 4.430

10.  Breed-predispositions to cancer in pedigree dogs.

Authors:  Jane M Dobson
Journal:  ISRN Vet Sci       Date:  2013-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.